Descrizione del progetto
Innovativo dispositivo per le crisi epilettiche notturne
In tutto il mondo, sono più di 50 milioni le persone che soffrono di epilessia e meno di un terzo di loro trova poco o nessun sollievo dai farmaci, in particolare per le crisi notturne. Il progetto NightWatch, finanziato dall’UE, ha sviluppato un dispositivo medico registrato che rileva i casi di gravi crisi epilettiche notturne e le segnala in pochi secondi agli operatori sanitari a distanza in modalità wireless. Il dispositivo comprende un braccialetto che misura la frequenza cardiaca e i movimenti, creando un algoritmo unico. Testato clinicamente, il dispositivo è in grado di rilevare oltre il 90 % di tutti i tipi di crisi epilettiche notturne urgenti, il che lo rende il sistema più affidabile in circolazione.
Obiettivo
More than 50M people worldwide suffer from epilepsy, characterized by uncontrolled seizures, and about 30% find no relief from those despite taking medication. Nocturnal seizures can be critical; each year at least 33.000 people in EU die of Sudden Unexpected Death in Epilepsy (SUDEP), 40% of which could be prevented by attending the seizures on time. This is a continuous challenge for patients and caregivers, with important social and societal consequences (anxiety, depression, lack of sleep), and high intramural care costs (over €20 billion per year in EU).
The NightWatch is a registered medical device that detects and notifies wirelessly remote caregivers in case of heavy nocturnal seizures in just few seconds. The bracelet uses a combination of heart rate and movement measurement, a unique AI algorithm conceived by three Dutch institutes specialised in epilepsy, automatically adapting to different patient patterns to minimize false alarm rate. It has been clinically tested and can detect > 90% of all types of urgent nocturnal seizures making it the most reliable system available.
The NightWatch targets caregivers, patients and professionals who seek an effective alarm system for severe nocturnal seizures. It improves their quality of life giving them peace of mind, higher level of independency, reduces cost of care by reducing the need for intramural attention, and prevents deaths caused by SUDEP. With a trend to-wards home care and self-monitoring pushing market growth (expected to reach €4.0 billion in 2019), wearables becoming the preferred type of seizure monitoring. EU leads the seizure monitor devices market (46%), followed by North America (28%).
NightWatch is the flagship product of LivAssured, a Dutch company created in 2013 as a spin-off to take over the commercial exploitation of the research results of the Tele-Epilepsy Consortium on nocturnal seizures. With its full commercial exploitation, we expect an accumulated profit of €19M and a ROI of 4
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
5261AD VUGHT
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.